Prostate Cancer

Relugolix is the first oral drug in this class to receive FDA approval, and it may eliminate some patients’ need to visit the clinic for certain treatments.

FDA approves Gallium 68 PSMA-11, the first drug for PET imaging of prostate-specific membrane antigen–positive lesions in patients with prostate cancer.

FDA lift clinical hold placed on the phase 1 PSMA-101-001 study of the chimeric antigen receptor T-cell therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer.

Bacteria in the gut may play a role in the treatment outcomes of patients with prostate cancer taking oral medications, according to a recent study.

The FDA grants fast track designation to the highly-selective N-terminal domain inhibitor EPI-7386 for the treatment of adult patients with metastatic castration-resistant prostate cancer.

Since 2004, the FDA has approved different treatments for advanced prostate cancer, adding almost 2-3 indications per year for the past 15 years.

On February 14, 2018, the FDA approved apalutamide (Erleada) by Janssen Biotech Inc for the treatment of nonmetastatic castration-resistant prostate cancer (NM-CRPC).